Backed by veteran investor Rakesh Jhunjhunwala, the gaming technology company had caught investors’ imagination over the past nine months. In recent weeks, though, the stock has been down in the dumps.

“Loan provisioning can be lower because of change in the IRAC norms because we expect credit costs to gradually come down for the bank.”

India VIX, a barometer of volatility, plunged over 5 per cent. But the movement of headline indices shows traders are not keen to go long ahead of an extended weekend.

The Nifty Bank index closed 1.34 per cent down at 39402.05.

“Sun Pharma expects to gain momentum and continue to focus on building the prescriptions for core specialty products.”

For the reported quarter, SBI reported a 42 basis points sequential decline in gross non-performing assets ratio to 4.9 per cent and a 25 bps decline in net NPA ratio to 1.52 per cent.

The Q2FY22 Gross Booking Revenue (GBR) stood at Rs 895.1 crore as compared to Rs 339 crore in Q2FY21, up by 164 per cent year on year and Rs 357 crore in Q1FY22, up by 151 per cent quarter on quarter.

“In terms of the collection efficiency, we are at 98.7% which is almost pre Covid levels and far better than last quarter which was 95.1.”

"Since the second stage closing could not be completed as per the agreed timelines, in the terms of the SPMA, InvaGen has received a notice of termination from Avenue," the Mumbai-based drug major said in a regulatory filing.

As of 30-Sep-2021, promoters held 38.4 per cent stake in the company, while FIIs held 37.77 per cent and domestic institutional investors had 10.96 per cent.